Fusion Antibodies lead drug targeted at Pancreatic Cancer PR Web (press release) A novel pre-clinical antibody drug being developed by Fusion Antibodies (Belfast, NI) is being targeted at Pancreatic Cancer. Early in-vitro data has shown significant efficacy in Pancreatic Cancer cell lines and the Company is now seeking new ... |
